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Abstract: Female mice (Black 6 strain) (C57BL/6) aged 6 weeks were subject to low dose strepto-
zotocin (STZ) treatment for five consecutive days to mimic type 1 diabetes mellitus (T1DM) with
insulitis. At two weeks after STZ injections, evaluation of the elevated glucose levels was used to
confirm diabetes. The diabetic mice were then subject to the transplantation of pancreatic β-cells
(MIN-6 line). Four groups of mice were studied. The first group was injected with saline-only acting
as the placebo surgery control, also known as SHAM group, the second and third groups were
injected with MIN-6 single cells and polyethylene glycol-modified dipalmitoyl-glycerol-phosphatidyl
ethanolamine (PEG-DPPE) modified MIN-6 single cells (500 µg per 1.106 cells), respectively, while
the fourth group was injected with hyaluronic acid (HA)-coated MIN-6 single cells (5 bilayers).
At seven- and fourteen-days following transplantation, the mice were euthanised. The renal and
pancreatic tissues were then collected and histologically analysed. The induction of diabetes in
female mice, through five-consecutive daily STZ injections resulted in inconsistent glycaemic levels.
Interestingly, this shows an incomplete diabetes induction in female mice, of which we attribute to
sex dimorphism and hormonal interferences. Transplantation failure of free-floating encapsulated
cells was unable to decrease blood glucose hyperglycaemia to physiological ranges. The result is
attributed to deprived cell–cell interactions, leading to decreased β-cells functionality. Overall, we
highlight the necessity of refining T1DM disease models in female subjects when using multiple
low-dose STZ injections together with transplantation protocols. Considerations need to be made
regarding the different developmental stages of female mice and oestrogen load interfering with
pancreatic β-cells susceptibility to STZ. The use of pseudo islets, cell aggregates and spheroids are
sought to improve transplantation outcome in comparison to free-floating single cells.
Keywords: diabetes induction; female animal model; transplantation
1. Introduction
Many animal studies use pancreatomy to induce a state of absolute insulin deficiency
and hyperglycaemia in order to mimic diabetes [1]. However, many other hormones
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(e.g., glucagon) and digestive enzymes are also extinguished when performing a total pan-
creatomy. Diabetes-inducing agents such as STZ selectively obliterates insulin-producing
cells in the pancreas while maintaining the remaining functionality of the organ. STZ
is a broad-spectrum antibiotic with unique toxic selectivity for β cells in the pancreas,
being used clinically for the treatment of metastatic insulinomas. STZ uptake into rodent
pancreatic β cells is mediated by GLUT2 receptor. STZ is equally diabetogenic whether
administered to fed or fastened mice [2], showing no competition with glucose for the
GLUT2 receptor.
Outside its therapeutic application, STZ has been used since early 1960s in diabetes
research in order to induce hyperglycaemia in rodents via selective destruction of β cells.
This effect is attributed to the nitroso moiety in STZ. Once inside the cell, this nitroso group
acts as a nitric oxide (NO) donor to create reactive oxygen species and induce cell death [3].
However, the cell death pathway greatly differs by the STZ posology adopted for the
induction of hyperglycaemia in mice. When delivered by intraperitoneal injection as a
single high dose (180–190 mg/kg body weight), STZ causes massive β-cell necrosis within
2–3 days after administration. One moderate dose (150 mg/kg body weight) in conjunction
of high fat diet can also accelerate β-cell endoplasmic reticulum stress which mimics type 2
diabetes mellitus with high toxicity and mortality rate. Whereas multiple low doses of STZ
mimics T1DM with insulitis [2].
STZ protocols for diabetes induction produce a reliable T1DM animal model, specifi-
cally applied in pre-clinical research related to the transplantation of allogenic and xeno-
geneic pancreatic β cells. However, from the array of immortal pancreatic β-cell lines
available for transplantation, MIN-6 cells originated from transgenic C57BL/6 mouse
insulinoma and capable of expressing an insulin-promoter/SV40 T-antigen construct are
one of the few immortal cell lines to retain glucose-stimulated insulin release [4]. The
transplantation of these cellular grafts embedded in a cell encapsulation coating is key
to protect pancreatic β cells from the host immune system [5], while maintaining cell
functionality and physiological insulin secretion patterns in response to blood glucose
concentrations [6].
However, animal research across all disciplines predominantly uses male subjects
instead of mixed or only female subjects. The incorporation of only male subjects in
animal research is likely to lead to poorer treatment outcomes for women in the future,
as studies have already revealed marked differences between male and females in many
basic biological processes [7]. The National Institute of Health (NIH) in the USA has been
developing policies encouraging the use of both male and female animal research subjects
and consideration of sex and biological variables [8].
In the context of T1DM pre-clinical research, when male and female mice are trans-
planted with two different stages of pancreatic cells derived from human embryonic stem
cells (endocrine progenitors and insulin-positive cells), the in vivo maturation of both
cell populations into insulin-secreting cells was accelerated in female recipients. The
oestradiol-2 (E2) hormone was the promoter of a faster β cells maturation [9].
In humans, women tend to have an increased glucose-stimulated insulin secretion
(GSIS) due to a higher GLP-1 production associated to the female E2 hormone [9]. E2
hormone also influences the immune system, which plays a central role in the development
of T1DM. The immunological effects of E2 on innate immune system show to be protective
against innate immune pro-inflammatory responses and prevents apoptosis of islets. E2
also protect islets from the adaptive immune response, where E2 hormone promotes the
expansion of immunosuppressive Treg cells. In ketosis-prone diabetes (KPD), which is a
form of type 2 diabetes mellitus, a male predominance is also observed. Interestingly, the
rare women developing KPD were in an anovulatory state, with decreased E2 levels [9].
Endocrine pancreas cell composition is known to vary according to pancreatic anatom-
ical location and amongst different species [10]. Moreover, the proportion of different
hormone-producing cells in the pancreas also differs between males and females of the
same species, possibly also contributing to the female resistance to diabetes induction.
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Studies suggest that islets from women have an average of 6% more β cells than men,
moreover, islet transplantation from female donors also show better outcomes than with
islets obtained from male donors [9].
In this context, sex dimorphism and hormonal variances may interfere with the induc-
ing effects of STZ. Herein, we assess the suitability of a T1DM protocol utilizing low-dose
STZ injections using solely C57BL/6 female mice subjects in a post-puberty developmental
stage, where mice present oestradiol hormones produced during the oestrous cycle. The
transplantation of encapsulated free-floating MIN-6 cells was also performed with the
ultimate aim of providing a pathway to decrease hyperglycaemia and reverse diabetes in
this female animal model that should resemble autoimmune T1DM.
2. Materials and Methods
2.1. Materials
HA, with an average molecular weight (MW) of 1.20 MDa and 0.1 MDa, was kindly
supplied by Shanghai Easier Industrial Development Co. LTD. (Shanghai, China) as
dry powder. Maleimido propionyl-polyethylene glycol-n-hydroxysuccinimide ester (Mal-
PEG-NHS), dipalmitoyl-glycerol-phosphatidyl ethanolamine (DPPE), 2,2′-dithiodipyridine,
dithiothreitol (DTT) and phosphate buffered saline (PBS) were purchased from Sigma
Aldrich (St. Louis, MO, USA). All other consumables necessary for cell culture including cell
culture medium, pipettes, flasks and plates were purchased from Thermofisher. Pancreatic
MIN-6 cells were provided by the I3Bs Research Group at the University of Minho, Portugal.
2.2. Animals
Female mice of Black 6 strain (C57BL/6) aged 6 weeks were housed in ventilated
cages of no more than 5 mice per cage with free access to food and water, at a controlled
temperature of 23 ◦C with 12 h light-dark cycles. All procedures were performed in
accordance with the European Directive 86/609/EEC and approved by the University of
Minho Animal Ethics Committee (SECVS 074/2016) and the Portuguese National Authority
(DGAV 014072).
2.3. Model for Diabetes Induction
All mice were subjected to low dose STZ treatment to mimic T1DM with insulitis. An
STZ solution was freshly prepared using sodium citrate pH 4.5 prior to be administered
intraperitoneally (50 mg/kg of body weight) once a day for five consecutive days. At the
time of the injections, mice were kept ad libitum fed. Diabetes development was assessed
by measurement of blood glucose levels (Freestyle Precision Neo, Abbott).
2.4. Conformal Cell Coating
MIN-6 cells, 30–40 passages, were cultured in a density of 10 × 106 cells/flask in high
glucose DMEM, supplemented with 10% FBS, 1% antibiotic/antimycotic, 10 mM sodium
pyruvate and 50 µM β-mercaptoethanol. Cell media was replenished every 3 days until
cell confluency was reached. Cells were trypsinised and the resulting free-floating single
cells were further used for different encapsulation processes (Figure 1).
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Free-floa ing single MIN-6 cells at a density of 1 × 106 were incubated with Mal-PEG-
DPPE at 500 µg.mL−1 for 30 min. Mal-PEG-DPPE synthesis is described elsewhere [11].
After, cells were centrifuged and washed with PBS 1X, resulting in PEG-DPPE modified
MIN-6 single cells. After washing, cells were centrifuged and the supernatant was removed.
Cells were incubated in solutions containing 1.8 mg ×mL−1 of different HA derivates in
DMEM. Synthesis of HA derivates carrying free thiol groups (HA-SH) and pyridine groups
(HA-PD) has been described elsewhere [12,13]. The first conformal layer was deposited
onto the surface of the cells by incubating HA-SH 0.1 MDa for 10 min. After the cells
were centrifuged and washed with PBS 1X, they were incubated with HA-PD 1.2 MDa
for 10 min. This first cycle is the first coating bilayer. For the second bilayer, cells were
incubated with HA-SH 0.1 MDa for 10 min. Then the cells were centrifuged and washed
with PBS 1X and were incubated with HA-PD 1.2 MDa for 10 min. For the third bilayer,
cells were incubated with HA-SH 1.2 MDa for 10 min. Then the cells were centrifuged and
washed with PBS 1X and incubated with HA-PD 1.2 MDa for 10 min. For the fourth and
fifth bilayers, cells were incubated with HA-SH 1.2 MDa for 10 min. Then the cells were
centrifuged and washed with PBS 1X and incubated with HA-PD 1.2 MDa for 10 min.
2.5. MIN-6 Graft Tr nsplantation
Diabetic mice were subject to the transplantation of pancreatic β cells (MIN-6 line).
Four groups of mice were used. Mice injected with saline-only (SHAM group), mice
injected with MIN-6 single cells, mice injected with PEG-DPPE modified MIN-6 single cells
and mice injected with HA-coated MIN-6 single cells.
Prior to the surgery, intramuscular (IM) injection (100 µL) of 90 mg/kg ketamine
(Imalgen; Meriel, Lyon, France) in combination with 0.65 mg/kg of the α2 adrenergic
receptor agonist medetomidine (Domitor; Pfizer, Paris, France) were used for anaesthesia
and sedation, respectively. Shaving and incision under the left rib was performed. A cell
suspension of 750,000 cells per mice or 10 µL of saline was injected under the left kidney.
Mice were sutured and they were given an IM injection (50 µL) of atipanezole 1 mg/kg
(Antisedant; Pfizer, Paris, France) as a sedative reverser. Mice were put to rest under
warm light.
2.6. Blood Glucose Control
Mice were assessed for up to 14 days post-transplantation to analyse diabetes reversion
through the measurement of blood glucose levels twice a week. Blood samples were
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collected from pricking the mice cheek with a needle. The blood droplet was placed in a
glucose strip and measured using a glucometer (Freestyle Precision Neo, Abbott). After
follow-up, mice were sacrificed for histological analysis
2.7. Dissection of Renal and Pancreatic Tissues
Mice were euthanised via CO2 inhalation at different time points. 7 days and 14 days
of after transplantation mice from each group (n = 5) were sacrificed for the collection
of renal and pancreas tissues to determine the leukocytic infiltration degree. Renal and
pancreatic tissues were retrieved and fixed using 4% formalin solution. Fixed kidneys and
pancreas were embedded in paraffin and cut in 5 µm thick sections using a microtome.
2.8. Histology
Haematoxylin and eosin were used to analyse graft-localised cell infiltration and
inflammation. All images were acquired using a CKX41 Olympus inverted microscope
(Tokyo, Japan) equipped with a DFK 31AU03 camera (The Imaging Source Europe GmbH,
Germany) and IC Capture software (The Imaging Source Europe GmbH, Germany).
2.9. Statistical Analysis
Data are presented as mean ± standard deviation (s.d.) and analysed using one-way
analysis of variance (ANOVA) followed by post-hoc Tukey’s HSD test. p-values < 0.05 (*)
were considered significant.
3. Results and Discussion
3.1. Animal Model for Diabetes Induction
Diabetes was induced in female mice via 5 consecutive low-dose STZ injections
(Supplementary Figure S1). The blood glucose levels of the female mice after 14 days of
the injections are shown in Table 1. The blood glucose levels of 20% of all mice subjected
to the induction were unable to achieve hyperglycaemia after 14 days of the last STZ
injection, with blood glucose levels falling between 100 and 149 mg/dL. By its turn, 32% of
the mice displayed little increase in blood glucose levels (150–199 mg/dL), however still
falling into a non-diabetic category. Moreover, 48% of the mice were successfully induced
with diabetes, showing high blood glucose levels above 200 mg/dL (hyperglycaemia).
These findings highlight that diabetes induction in female mice is associated with sexual
dimorphism assigned to the oestradiol hormone.
Table 1. Blood glucose levels of mice at 14 days after STZ induction and before transplantation.
Blood Glucose Level SHAM Cells Only Cell Encapsulation Cell with Surface Modification Total (%)
100–149 mg/dL 2 2 2 2 20
150–199 mg/dL 4 1 3 5 32
200–299 mg/dL 2 4 3 1 25
300–399 mg/dL 1 3 2 1 18
≥400 mg/dL 1 0 0 1 5
Sex differences in physiology begin early in development, due to a combination of
genetic and hormonal cues which continue after puberty. In multiple rodent models of
diabetes in which β cell failure occurs, sex dimorphism is also observed. It is known
that female mice will develop insulitis, with modest hyperglycaemia (around 200 mg/dL)
14 days following the STZ injections. While male mice develop diabetes with severe
hyperglycaemia (>400 mg/dL) during the course of the 5 days of injection [14,15]. These
differences are assigned to oestradiol, the major female oestrogen steroid hormone, which is
presumed to protect the β cell from oxidative stress-induced apoptosis [16]. The protective
effect of oestradiol in the β cells against oxidative stress is believed to be mediated by
three oestrogen receptors expressed in β cells, ER-alpha, ER-beta and G-protein coupled
oestrogen receptor [17].
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In this study female mice aged 6 weeks old were used to recreate a T1DM model. At
this age mice already achieved puberty and are considered adults, thus the oestrogen levels
in the female mice play a role in the decreased efficiency of STZ induction [18]. Although
the results shown in this project have great variability regarding diabetes induction and
hyperglycaemia achievement, it corroborates that more research and adaptation of current
protocols have to be made in order to better characterise disease models in female subjects
(shown in Figure 2).
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We speculate that, for mice aged <3 weeks which are in a pre-puberty, the induction
of diabetes can potentially be more reliable as these mice are not in their reproductive cycle
yet, thus the oestrogen dependant effect on STZ would not be present. On this point, it is
worth noting that in humans T1DM onset starts in early childhood [19], and utilizing mice
at a pre-puberty stage is a good strategy to reproduce onset in early childhood.
However, T1DM induction in female mice over 3 weeks old is possible with the
ablation of the oestrogen hormone. In this scenario, ovariectomy could be implemented
together with STZ induction [20]. However, this method of oestrogen ablation is known to
produce important side effects. So as an alternative, STZ induction could be potentially
administered concomitantly with oestrogen receptor antagonists, like tamoxifen, for the
ablation of oestrogen in female mice at reproductive stages [21].
Moreover, the great variability of hyperglycaemia within female mice (reported in
Table 1) is sought to be a consequence of each individual rodent reproductive cycle. In
rodents the reproductive cycle, called the oestrous cycle, lasts approximately 4–5 days (in
humans it is called the menstrual cycle, and lasts approximately 28 days). The oestrous
cycle has four stages (proestrus, oestrus, metestrus and dioestrus). Each stage lasts for
approximately one day [22]. Proestrus stage corresponds to the pre-ovulatory day, when
E2 increases and consequently, during the night, luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) surge and ovulation occurs. In the oestrus stage, E2 remains
elevated throughout the morning and falls back to basal levels in the afternoon. In the
metestrus stage, plasma E2 concentration is low. Finally, in the dioestrus stage, E2 levels
start to increase [23]. Considering that 52% of all mice did not achieve hyperglycaemia,
and 48% of the mice were successfully induced with diabetes, showing high blood glucose
levels, it may be possible that the start of the oestrous cycle (high E2 levels) coinciding
with the start date of STZ injection, decreases the efficacy of STZ induction. While starting
the STZ induction in the metestrus stage, where low levels of E2 are found, may increase
STZ-induced cell toxicity and higher diabetes induction efficiency rates.
In humans, a further subtype of T1DM affects an older demographic group known
as Late Onset Autoimmune Diabetes of Adults (LADA) [24]. In recent epidemiological
studies, T1DM in children has shown no gender predilection, due to the pre-puberty lack
of hormone interference at disease onset. However, in LADA, where the average onset
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T1DM is at the age of 40 years old, there is a significant difference (p < 0.001) in gender-
prevalence. At this age group, LADA has been shown to affect 80% of males and only 20%
of females. Showing that women are less likely to develop LADA in their reproductive
years (levels of oestrogen around 400 pg/mL) up to their pre-menopausal stage. However,
it is noted that after the age of 45 years old, onset of LADA decreases its incidence in men
to 40%, but skyrockets in women (60%) [25]. Once women reach menopause age and the
oestrogen levels drop below 30 pg/mL, pancreatic β-cell populations are more susceptible
to cell death. In this regard, the use of post-reproductive female mice subjects (aged above
750 days) may be considered to increase hyperglycaemic state after multiple low-dose STZ
injections in T1DM models [18].
3.2. In Vivo Transplantation in the Renal Subcapsular Space
Deviation in mice, the kidneys are located retroperitoneally, where the left kidney is
readily visible and can be accessed more easily in comparison to the right kidney, which is
located under the small intestine and adjacent to the liver [26]. In the kidneys, the adrenal
glands are in close proximity to each renal cranial pole, and they can be distinguished by
the light orange coloration due to steroid hormone production [27]. The kidneys in rodents
are unilobular, unipapillary and unipyramidal, in contrast to human kidneys which are
multilobular, multipapillary and multipyramidal. On a cross-section of the kidney, four
main structures can be seen: the capsule, the cortex, the medulla and the papilla which
extend deep into the renal pelvis. The capsule is made of epithelial and fat tissue. In
the renal cortex, the glomeruli (with an average diameter of 73.4 µm) and the proximal
convoluted tubules can be found. In the medulla (pyramid) the medullary capillary plexus
is found. Little interstitial connective tissue is found in the kidney of rodents in contrast
to kidneys of humans [26]. In this study MIN-6 cells were injected under the sub-capsule
membrane of the kidney as single-cell treatments as shown in Supplementary Figure S2.
Five mice have died at day 3 post-transplantation. Of the ten mice for each group,
three mice died from the group implanted with PEG-DPPE cell surface modification, one
mouse died from the group implanted with HA encapsulated cells, and one mouse died
from the SHAM group. These deaths are attributed to stitch opening and infection at
the incision site. After the transplantation, mice had their blood glucose concentrations
recorded for 14 days post transplantation (Figure 3).
In Figure 3, although there is no significant difference in blood glucose levels for the
different groups over time (apart from cells only group), it can be seen that at day 0 (prior
to transplantation) all mice had reached mild hyperglycaemia (200–300 mg/dL), except
for the cell surface modification group. However, if we observe the SHAM group on day
3 after transplantation, we can notice an ongoing rise in blood glucose levels. This result
suggests that diabetes induced by STZ was not complete after 14 days as suggested by
the literature [14,15]. On day 7, we can observe a slightly decrease of blood glucose level,
which is associated with β-cell recovery due to an incomplete β-cell destruction [16]. When
analysing the pancreas of mice, islets are unevenly distributed throughout the pancreas,
and are present in both interlobular (Figure 4A) and periductal/perivascular (Figure 4B)
locations [28]. In the islets of mice, β-cell populations are typically clustered in the centre
of the islet and surrounded by other islet cell types, whereas in humans all islet cells are
homogenously intermingled [29].
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were stain d using haematoxylin and eosin.
Regarding the morphology of the islets after treatment with STZ, their architecture is
expected to be largely disrupted [30]. However, as seen in Figure 4C, islets did not show
morphological changes nor boundary irregularities. Moreover, no infiltration of immune
cells was observed in the histological analysis of the pancreas of STZ-induced diabetic mice.
In this scenario, considering the results presented, diabetes induction cannot be assured
only 14 days after STZ injections. It is recommended to consider extending the induction
for at least 21 days after STZ injections or increasing the daily dose of STZ.
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Figure 5. Histology analysis of the kidneys after 14 days post-transplantation of MIN-6 single cells. Saline group (A,B), cells
only group (C,D), and encapsulated cells (E,F). Immune cell infiltration is shown (*). Lower magnification 10×, scale bar
100 µm. Higher magnification 40×, scale bar 50 µm.
Furtherm re, in Figur 3, results sho that non-encapsulated single cells (cells only
group) were able to decrease hyperglycaemia over time to normal physiological levels
(<200 mg/dL). This was not observed in mice transplanted with encapsulated and surface-
modified cells. We hypothesise that non-encapsulated cells were able to interact with each
other and were probably able to form clusters to mimic a pseudo-islet. This hypothesis
has been confirmed in the histological analysis of the renal tissue after transplantation. In
Figure 5A,B, the saline transplanted group (SHAM) shows the normal appearance of the
renal capsule and the underlying renal cortex. In Figure 5C,D, the histological analysis
of the mice transplanted with naked cells, shows that the MIN-6 cells are grouped and
located between the renal capsule and the renal cortex. Images also show graft infiltration
with leukocytes. Infiltration of immune cells have also been reported by other studies at
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the 2-week transplantation mark. The degree of leukocyte infiltration is maximum at the
first two weeks after transplantation and subsequently decreases [28].
Unfortunately, MIN-6 cells were not able to be found in the histological images of
various slices of the kidneys of mice transplanted with encapsulated and surface engineer-
ing cells (Figure 5E,F). This finding confirms our hypothesis that surface-modified and
encapsulated cells were deprived from cell–cell interaction, unable to form clusters similar
to islets. This has also implications in β-cell functionality. Functional loss (measured by
insulin expression, insulin content and glucose-stimulated secretion) is correlated with a
decreased cell–cell interaction [31]. Other studies have also demonstrated this pattern of
functionality associated to MIN-6 cell aggregates and single cells [32]. Another important
point to highlight is that MIN-6 cells are anchorage-dependent cells. When single cells are
encapsulated, they are denied attachment to one-another or to surrounding ECM, which
likely triggers anoikis.
4. Conclusions
It is known that diabetes is achieved when levels of blood glucose are higher than
200 mg/dL. Reversion of diabetes and transplantation success is defined as the ability to
reach non-fasting blood glucose levels under 250 mg/dL within five days of transplantation.
Graft rejection is defined as two consecutive measurements above 300 mg/dL in mice
after normoglycemia is achieved. T1DM induction disease protocols have been established
using male mice and results here show that these protocols do not demonstrate a viable
option to induce diabetes in female mice. This result is hypothesised to be a consequence
of sexual dimorphism characteristics and hormonal interferences. As a result of these
findings, we suggest the following T1DM-inducing protocol modifications:
• Increase the daily dose of STZ to above 50 mg/kg.
• If maintaining the 50 mg/kg dose a day, it may be advisable to increase the number of
induction days above the 5 consecutive daily injections;
• In order to guarantee complete diabetes induction without β recovery, the post-
induction period should be increased from 14 days to 21 days;
• Assess the interference of the oestrous cycle and the levels of oestrogen (E2) in the
efficacy of STZ induction of diabetes in female mice aged >3 weeks (post-puberty
stage);
• Assess the feasibility of using female mice aged <3 weeks (pre-puberty stage) to induce
diabetes using STZ, as levels of oestrogen are neglectable. At this stage, T1DM may be
better represented, as in humans, T1DM onset generally occurs in early childhood.
Lack of cell–cell interaction influences transplantation outcome and diabetes reversion
in this work, with deficient insulin secretion is unable to control hyperglycaemia. To
confirm this hypothesis, we suggest the following:
• Development of pseudo-islet aggregates using MIN-6 cells;
• Encapsulation of pseudo-islet;
• Assessment of glucose-induced insulin secretion;
• Transplantation of encapsulated pseudo-islet;
• Histological assessment of pseudo-islet aggregates under the kidney capsule
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13111925/s1. Figure S1 (A) Intraperitoneal injection of STZ. (B) Mice are kept in
cages with ad libitum fed regimen. Figure S2 MIN-6 cell transplantation. A) Abdominal viscera of
female mice. (B) Intramuscular administration of anaesthetics. (C) Topical application of Vaseline to
protect eyes from drying during surgery, lateral hair removal for incision. (D) Graft injection inside
the kidney capsule. (E–F) Suture and stiches. (G) Post-operation recovery.
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